AR and prostate carcinoma: As a result, therapies targeting the AR pathway, such as next-generation AR antagonists and agents that inhibit androgen biosynthesis, remain the cornerstone of CRPC management, emphasizing the clinical importance of AR in the resistance and evolution of advanced prostate cancer.